Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Terminated(1)
Other(1)

Detailed Status

Terminated1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

terminated133%
completed133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_2

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

NCT00942825
terminatedphase_2

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

NCT00509366
unknownphase_3

Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer

NCT01303926

Clinical Trials (3)

Showing 3 of 3 trials
NCT00942825Phase 2

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

Completed
NCT00509366Phase 2

Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer

Terminated
NCT01303926Phase 3

Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3